Johnson & Johnson outperforms expectations with robust 2024 results and 2025 outlook

ByInvestment Club

Overview

Johnson & Johnson (J&J) demonstrated solid financial performance in Q4 and full-year 2024, driven by strong results across its Innovative Medicine and MedTech segments, as well as a strategic focus on efficiency and innovation.

Joaquin Duato, Chairman and Chief Executive Officer, placed a particularly important emphasis on the investments made by the company in the recently concluded year, looking to the future with great confidence: “2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation. As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.”

Q4 2024 vs. Q4 2023:

  • Revenue increased to $22.52bn (+5.3% YoY), supported by strong performance in the U.S. and MedTech sales growth.
    • For the Innovative Medicine, revenue increased to $14.33bn (+4.4% YoY), with oncology leading growth due to successful products like Darzalex (+20.9% YoY) and Erleada (+20.9% YoY).
    • For the MedTech, revenue reached $8.19bn (+6.7% YoY), driven by cardiovascular innovations and the inclusion of Shockwave Medical.
  • Adjusted net income was $4.95bn (-11.1% YoY), primarily due to higher restructuring and amortization expenses.
  • Adjusted EPS for Q4 2024 was $2.04 (-10.9% YoY), reflecting strategic investments and one-time expenses.

Full-Year 2024 highlights:

  • Full-Year revenue rose to $88.82bn (+4.3% vs. 2023), with steady growth across geographic regions, the most significant regional sales growth occurring in the U.S. (+8.3% YoY).
  • Net Earnings from continuous operations increased to $14.07bn (+5.6% YoY).
  • J&J reported full-year EPS of $5.79 (+11.3% vs. 2023) and adjusted EPS of $9.98 (+0.6% vs. 2023), both reflecting a $(0.67) impact from acquired IPR&D charges on various transactions throughout the year.

Johnson & Johnson’s 2025 guidance reflects confidence in sustained growth, with projected operational sales growth of 2.5% to 3.5% and adjusted operational EPS expected in the range of $10.75 to $10.95, representing a robust 8.7% growth at the midpoint. This outlook underscores the company’s strong positioning and commitment to delivering value through innovation and operational excellence.

J&J plans to further enhance its portfolio with pipeline advancements in oncology, immunology, and MedTech innovations.

Author: Ionuț-Adrian Lazar

Similar Posts